In a child with hypercalcemia, hyperchloremia, elevated albumin, alkaline phosphatase, and alanine aminotransferase, what is the appropriate diagnostic work‑up and initial management?

Diagnostic Work-Up and Initial Management of Pediatric Hypercalcemia

In a child presenting with hypercalcemia, hyperchloremia, elevated albumin, alkaline phosphatase, and ALT, immediately measure serum PTH (after correcting any vitamin D deficiency) to differentiate PTH-dependent from PTH-independent causes, as this single test determines the entire diagnostic and therapeutic pathway. 1

Initial Diagnostic Algorithm

Step 1: Measure Serum PTH

• If PTH is elevated or inappropriately normal → Primary hyperparathyroidism (PHPT) pathway
• If PTH is suppressed → Non-parathyroid causes (malignancy, vitamin D toxicity, granulomatous disease)

The combination of hypercalcemia with hyperchloremia and elevated alkaline phosphatase strongly suggests PHPT, as the calcium-chloride relationship is characteristic of this condition 2.

Step 2: Age-Specific Genetic Considerations

Genetic testing should ALWAYS be performed in pediatric PHPT - a germline mutation is identified in 40% of children/adolescents and 70% of infants 1. Order comprehensive gene panels including:

• CaSR, GNA11, AP2S1 (calcium-sensing receptor pathway defects)
• MEN1, CDKN1B, CDKN2B, CDKN2C, CDC73, RET, GCM2 (parathyroid proliferation genes)

The age of presentation predicts genetic etiology: infants predominantly have CaSR pathway mutations (94%), while children/adolescents have proliferative gene mutations (69%) 1.

Step 3: Assess Target Organ Damage

Renal evaluation:

• Low-dose CT urography (preferred over ultrasound) to detect nephrocalcinosis and urolithiasis 3
• Urinalysis - sterile pyuria may be an early indicator of hypercalcemia 4
• 24-hour urine calcium (or spot calcium/creatinine ratio)

Bone evaluation:

• DEXA scan for bone mineral density
• Consider skeletal survey if fractures suspected

In children with PHPT, 80% present with severe symptomatic disease, commonly with renal complications (nephrocalcinosis, lithiasis) or bone complications (fragility fractures) 1.

Step 4: Parathyroid Localization (if PHPT confirmed)

First-line imaging:

• Parathyroid ultrasound (sensitivity 89%, specificity 58% in pediatrics) 1
• Combined with either:
  • Double isotope scintigraphy (123I/99mTc-Sestamibi) (sensitivity 95%, specificity 50%), OR
  • 18F-Choline PET-CT 3

If initial imaging inadequate → Refer to expert center for MRI or 4D CT 3.

Differential Diagnosis Considerations

PTH-Dependent Causes:

1. Primary hyperparathyroidism (adenoma >50% of cases, or diffuse hyperplasia)
2. Familial hypocalciuric hypercalcemia (FHH) - heterozygous CaSR mutations
   • Key distinguishing feature: relative hypocalciuria despite hypercalcemia
   • Calculate calcium/creatinine clearance ratio (<0.01 suggests FHH)

PTH-Independent Causes:

1. Malignancy (rare in children but consider acute lymphoblastic leukemia) 5
2. Vitamin D disorders (CYP24A1 mutations causing idiopathic infantile hypercalcemia)
3. Williams-Beuren syndrome 4
4. Granulomatous disease

Elevated Liver Enzymes Context:

The elevated ALT and alkaline phosphatase require consideration of:

• Alkaline phosphatase elevation in PHPT reflects bone turnover, not necessarily liver disease 2
• Verify liver-specific fraction if hepatic pathology suspected
• Elevated albumin suggests dehydration from hypercalcemia rather than liver synthetic function 6

Initial Management

Acute Treatment (Severe Hypercalcemia >3.5 mmol/L or Symptomatic):

Immediate measures:

1. Aggressive IV hydration with normal saline (first-line)
2. Loop diuretics (furosemide) - only AFTER adequate hydration 7
3. Bisphosphonates (zoledronic acid) for refractory cases
   • Single dose can normalize calcium within 72 hours 5, 4
   • Particularly effective in severe neonatal PHPT and malignancy-associated hypercalcemia

For severe neonatal PHPT (>3.5 mmol/L with CaSR mutations):

• Calcimimetics (cinacalcet) are now preferred over surgery for heterozygous CaSR mutations 1
• Efficacy is limited in bi-allelic CaSR mutations
• Bisphosphonates show variable efficacy and may cause rebound PTH elevation 1

Definitive Treatment for PHPT:

Surgery is the definitive treatment and should be performed by a pediatric endocrine surgeon 1. Indications include:

• Symptomatic hypercalcemia
• Target organ damage (renal or bone complications)
• Hypercalciuria
• Age <50 years (applies to all pediatric patients)

Surgical outcomes in children are excellent: >90% cure rate with minimal permanent complications or recurrence 1.

Critical Pitfalls to Avoid:

1. Do NOT delay PTH measurement - this is the critical branch point
2. Do NOT assume FHH is benign - severe neonatal forms require aggressive treatment
3. Do NOT perform surgery without genetic testing - MEN syndromes require different surveillance
4. Do NOT use loop diuretics before adequate hydration - worsens volume depletion
5. Do NOT attribute neuropsychological symptoms to other causes - lethargy, depression, behavioral changes, and school difficulties are common presenting features in pediatric PHPT 1
6. Do NOT overlook sterile pyuria - may be the earliest clinical clue to hypercalcemia 4

Refer to expert multidisciplinary team if: poorly localized lesion, suspected syndromic form, revision surgery needed, or severe neonatal presentation 3, 1.